TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Sep 12, 2022 09:00 JST
Source:
Eisai
Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Clinical Studies
TOKYO, Sep 12, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study 305, Study 301 and Study304) evaluating the efficacy of eribulin mesylate (marketed as HALAVEN) versus other chemotherapies (Treatment of Physician's Choice [TPC], capecitabine, and vinorelbine, respectively) in patients living with metastatic breast cancer (mBC) whose tumors have low or no HER2 expression. These data were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22), held virtually and in-person in Paris, France from September 9-13, 2022.
The HER2-low breast cancer subtype is a newly defined subset consisting of tumors that would have previously been considered HER2-negative based on an immunohistochemistry (IHC) assay and an in situ hybridization (ISH) assay. HER2-low tumors express low amounts of the HER2 protein, but not enough to be considered HER2-positive. HER2-low is defined as an IHC of 1+ or 2 with a negative ISH. Of the approximate 288,000 new cases of female breast cancer expected to be diagnosed in the U.S. in 2022,(1) it is estimated that approximately 80-85% of patients would previously have been considered to have the HER2-negative subtype. Of those patients, about 60% would now be considered to have the HER2-low subtype.(2)
"In this post-hoc analysis, the outcomes seen in mBC patients whose tumors are considered HER2-low are consistent with the results of the three pivotal Phase 3 clinical trials," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "As the oncology community's understanding of mBC continues to evolve, it's important that we continue to evaluate the role of existing therapies in new contexts to contribute to the body of knowledge that is available to health care professionals."
(1) National Institutes of Health, National Cancer Institute website, "Cancer Stat Facts: Female Breast Cancer":
https://seer.cancer.gov/statfacts/html/breast.html
(2) U.S. FOOD & DRUG ADMINISTRATION website, "FDA Approves First Targeted Therapy for HER2-Low Breast Cancer": bit.ly/3xc0N7q
For more information, visit www.eisai.com/news/2022/pdf/enews202266pdf.pdf.
Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
More Press release >>
Latest Press Release
Special Autumn Event: "Anime Tokyo Station Autumn Festival"
Nov 20, 2025 13:00 JST
ANIME TOKYO STATION ON ROBLOX: New Game "ANIME SKILL TCG" Out Now!
Nov 20, 2025 11:00 JST
DENSO and DELPHY Sign Joint Development Agreement to Accelerate Data-Driven Smart Horticulture
Nov 19, 2025 23:41 JST
NEC Presents the Decarbonization Potential of its CropScope Agricultural Solution at COP30
Nov 19, 2025 23:15 JST
Fujitsu recognized as the only Japan-headquartered company to be an Emerging Leader in Gartner(R) Emerging Market Quadrant for Generative AI Engineering
Nov 19, 2025 22:40 JST
Kingsoft Announces 2025 Third Quarter Results
Nov 19, 2025 17:47 JST
Mazda Begins Demonstration Experiment of Onboard CO2 Capture System
Nov 18, 2025 00:38 JST
Pushing Hydrogen Engine Technology to New Heights in the Super Taikyu Series Final Race
Nov 18, 2025 00:00 JST
Fujitsu launches business creation lab in collaboration with AWS Japan
Nov 17, 2025 23:41 JST
NTT DOCOMO Achieves Successful Outdoor Trial of AI-Driven Wireless Interface Toward 6G
Nov 17, 2025 23:05 JST
Destinator Earns the Highest Rating of Five Stars in 2025 ASEAN NCAP
Nov 17, 2025 22:32 JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Nov 17, 2025 22:08 JST
NEC Advances Research Information Infrastructure for Open Science
Nov 17, 2025 21:38 JST
Mitsubishi Shipbuilding Delivers Large Car Ferry KEYAKI to Shin Nihonkai Ferry and Japan Railway Construction, Transport and Technology Agency
Nov 17, 2025 21:00 JST
Hitachi Employee Receives the "Chop Wood Carry Water Award" from the Global OSS Organization CNCF for Leading the Establishment of Official Community in Japan
Nov 14, 2025 21:06 JST
The University of Osaka D3 Center and NEC Demonstrate Wide-Area Distributed Campus AI Processing Platform
Nov 14, 2025 00:41 JST
Toyota to Invest Up to $10 Billion Additional in Its U.S. Operations Over the Next Five Years
Nov 14, 2025 00:08 JST
MHI Thermal Systems Launches Magnetic Bearing Centrifugal Chiller "ETI-N" Series for Japanese Market
Nov 13, 2025 23:34 JST
MHI Completes Joint Demonstration with Kirin Group for Automation of Warehouse Operations, and Truck Loading and Unloading
Nov 13, 2025 23:00 JST
JCB launches second round of Shopping Mall Shuttle Free Ride Campaign in Guam
Nov 13, 2025 11:00 JST
More Latest Release >>